Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13005MR)

This product GTTS-WQ13005MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13005MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6050MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ4919MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ1147MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ1617MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ14133MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ10980MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ410MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ14060MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3918
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW